Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | PHASE1 | RECRUITING | 66 | — | — | Nov 13, 2025 | Oct 1, 2032 | Apr 7, 2026 | 13 | United States, Canada |
The incidence of dose limiting toxicities (DLTs) and other safety parameters (including but not limited to treatment emergent adverse events \[AEs\], serious adverse events \[SAEs\], and clinical laboratory abnormalities)
| Arm | Type | Description |
|---|---|---|
| ALLO-329, Cyclophosphamide | EXPERIMENTAL | Participants receive ALLO-329 following lymphodepletion regimen comprised of cyclophosphamide. |
| ALLO-329 | EXPERIMENTAL | Participants receive ALLO-329 without a lymphodepletion regimen. |
| Name | Type | Description |
|---|---|---|
| ALLO-329 | GENETIC | An allogeneic CAR T cell therapy targeting CD19 and CD70 |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: 1. Adults ≥ 18 to \< 70 years of age. 2. Adequate hematological function and liver, cardiac, and pulmonary function. 3. A highly sensitive urine pregnancy test or serum pregnancy test (for females of childbearing potential) negative at screening. All participants of childbearing...